A Phase I/II Study Evaluating the Safety and Efficacy of Nilotinib Combined With Mitoxantrone, Etoposide, and High-Dose Cytarabine (NOVE-HiDAC) Induction Chemotherapy Followed by Consolidation Therapy for Poor-Risk Patients With C-kit Positive Acute Myeloid Leukemia (AML) up to Age 65
Overview
- Phase
- Phase 1
- Intervention
- NOVE-HiDAC
- Conditions
- Acute Myeloid Leukemia
- Sponsor
- University Health Network, Toronto
- Enrollment
- 12
- Locations
- 1
- Primary Endpoint
- To determine the maximum tolerated dose (MTD) of nilotinib when combined with the NOVE-HiDAC regimen (mitoxantrone, etoposide, and modified high-dose cytarabine).
- Status
- Terminated
- Last Updated
- 10 years ago
Overview
Brief Summary
This is a phase I/II open-label study that is evaluating the toxicity and efficacy of nilotinib combined with mitoxantrone, etoposide, and high-dose cytarabine (NOVE-HiDAC) chemotherapy for patients with poor-risk acute myeloid leukemia (AML). There are two parts to the study. The first part (Phase I) will determine the maximum dose of nilotinib that can safely be given when combined with NOVE-HiDAC. This dose will then be used in combination with the NOVE-HiDAC regimen in the second part of the study (Phase II), which will evaluate the antileukemic activity of the treatment. The patients who achieve complete remission from the induction therapy (1 cycle) will then receive consolidation therapy combined with nilotinib (maximum of 2 cycles).
The patient population for this study will have AML and will fall into a poor risk category. This means they have persistent leukemia after induction therapy, they relapse within two years of achieving complete remission with induction therapy, or they have certain poor risk features at diagnosis. The AML cells will also be positive for c-kit (a stem cell factor receptor), which is involved in cancer cell growth. Nilotinib is a drug that blocks the effects of c-kit. Using this drug in combination with chemotherapy may improve ability of the chemotherapy drugs to kill leukemia cells. This may then increase the chances of the leukemia going into complete remission.
Investigators
Eligibility Criteria
Inclusion Criteria
- •AML as defined by WHO (World Health Organization) criteria, all subtypes except APL (acute promyelocytic leukemia).
- •One of the following poor risk features:
- •Persistent leukemia (at least 10% bone marrow blasts) after induction therapy, consisting of cytarabine 100-200 mg/m2 plus an anthracycline.
- •Relapse within two years of achieving complete remission with such induction therapy. Any consolidation therapy is acceptable, including stem cell transplantation.
- •No prior inductions, but antecedent myeloproliferative disorder or CMML (chronic myelomonocytic leukemia) (These patients are given NOVE-HiDAC as frontline therapy at Princess Margaret Hospital).
- •Positivity for c-kit (CD117) in at least 30% of blasts as measured by flow cytometry. For relapsed patients, this will be assessed at the time of relapse. For primary induction failures the initial diagnostic sample may be used.
- •ECOG performance status \< 3 (see Appendix I).
- •Patients must have the following laboratory values within normal limits (WNL) at the local institution lab or corrected to WNL with supplements prior to first dose of study medication.
- •Potassium (WNL)
- •Magnesium (WNL)
Exclusion Criteria
- •Active uncontrolled infection.
- •Active CNS (central nervous system) leukemia
- •Serum creatinine \> 200 umol/L.
- •Serum bilirubin \> 1.5 x ULN, AST (aspartate aminotransferase) or ALT (alanine aminotransferase) \> 2x ULN (upper limit of normal).
- •Serum amylase and lipase \> 1.5x ULN
- •Left ventricular ejection fraction \< 50%
- •Impaired cardiac function including any of the following:
- •Long QT syndrome or a known family history of long QT syndrome
- •History or presence of clinically significant ventricular or atrial tachyarrhythmias
- •Clinically significant resting bradycardia (\< 50 beats per minute)
Arms & Interventions
NOVE-HiDAC and Nilotinib
All patients will be receiving nilotinib combined with mitoxantrone, etoposide and high-dose cytarabine reinduction therapy. Patients achieving complete remission will receive consolidation therapy with nilotinib combined with high-dose cytarabine and mitoxantrone.
Intervention: NOVE-HiDAC
NOVE-HiDAC and Nilotinib
All patients will be receiving nilotinib combined with mitoxantrone, etoposide and high-dose cytarabine reinduction therapy. Patients achieving complete remission will receive consolidation therapy with nilotinib combined with high-dose cytarabine and mitoxantrone.
Intervention: Nilotinib
Outcomes
Primary Outcomes
To determine the maximum tolerated dose (MTD) of nilotinib when combined with the NOVE-HiDAC regimen (mitoxantrone, etoposide, and modified high-dose cytarabine).
Time Frame: 2 years
To determine the maximum tolerated dose (MTD) of nilotinib combined with mitoxantrone, etoposide, and modified high-dose cytarabine (NOVE-HiDAC) induction chemotherapy followed by consolidation chemotherapy for patients with poor risk c-kit positive AML.
To evaluate the toxicity of the treatment regimen.
Time Frame: 2 years
To determine the complete response (CR) rate of this combination at the maximum tolerate dose (MTD) of nilotinib.
Time Frame: 2 years
Secondary Outcomes
- To determine the disease-free survival of this combination.(2 years)
- To evaluate the pharmacodynamic effects of nilotinib on pERK and pAKT (phosphorylated ERK and AKT) in AML cells in vivo.(2 years)
- To correlate clinical responses with the degree of pAKT and pERK inhibition achieved in vivo.(2 years)
- To correlate the degree of pAKT and pERK inhibition with nilotinib pharmacokinetics.(2 years)
- To correlate pAKT and pERK inhibition with c-kit mutations.(2 years)